2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1698 High success rate for rapid cytogenetic test and factors contributing to failed karyotype analysis - an NCI myelomatch and SWOG report on the first 1000 enrolled patients

Shane McClung, Kate Kroeger2, Megan Othus, PhD3, Xiaoyu QU, PhD, FACMG4, Julie S. Biggerstaff5, Sewan Gurung6, Brent Wood, MD, PhD7, Cecilia CS Yeung, MD, Professor Pathology8, Lyndsay Harris, MD9, Mark R. Litzow, MD10, Harry Erba, MD, PhD11, Jerald Radich, MD12, Shahanawaz Jiwani, MBBS, PhD13, Richard F. Little, MD14, Min Fang, MD, PhD, FACMG15
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Children's Hospital of Los Angelous, Los Angelous, California, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 National Cancer Institute, Rockville, Maryland, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Duke University, Durham, North Carolina, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 National Cancer Institute, Rockville, Maryland, United States
14 National Cancer Institute, Rockville, Maryland, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Introduction: MyeloMATCH is an NCI precision medicine initiative for newly diagnosed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Diagnostic screening studies are performed at centralized testing laboratories, the Molecular Diagnostics Network (MDNet) labs, on fresh bone marrow (BM) or peripheral blood (PB) samples under an investigational device exemption (IDE). Results from karyotype analysis, fluorescence in situ hybridization (FISH), and NCI-myeloid assays inform ELN/IPSS risk stratification and patient assignment to several genetically driven treatment subprotocols within the myeloMATCH portfolio within four days of sample receipt. SWOG AML trials showed a 10% failure rate for karyotype analysis at local laboratories (Medeiros 2014) while more recent literature described failure rates between 6 and 8.8% (Javed 2023). Here we present our experience on the first 1000 patients enrolled in myeloMATCH and factors that impact karyotype success from this prospective clinical trial with rapid testing.

Methods: The first 1000 consecutive patients enrolled in myeloMATCH were included in this analysis. We examined results from karyotype analysis performed at the MDNet lab, IDE site #002 (Fred Hutch Clinical Cancer Genomics Lab), to correlate assay success with sample characteristics and preanalytical variances including delayed draw-to-test initiation time (beyond the usual 1-2 days in transit), presence of clots, sample volume, cell count concentration (million cells/ml), and total cells received. Successful karyotype analysis is defined as at least 20 metaphase cells regardless of abnormalities or less than 20 with clonal abnormalities. Invalid karyotype analysis is defined as normal results obtained from less than 20 metaphase cells. Incidence rates were compared with Fisher’s exact test.

Results: Of the first 1000 patients enrolled in myeloMATCH, 165 (16.5%) with disqualifying diagnosis were excluded. Of the 835 eligible patients, AML diagnosis was confirmed in 91.5% and MDS in 8.5%. BM accounts for 88% while PB was 12%. In 94% of patients, cytogenetic results were available prior to the 4th day treatment assignment call with a median time of 70 hours from sample receipt to reporting. Successful karyotype results were obtained from 720/736 (97.8%) BM samples and 95/99 (96.0%) PB samples; invalid results were from 16 (2.2%) BM and 4 (4.0%) PB samples with an overall failure rate of 2.4%. In comparison, historical data on 100 Fred Hutch local samples showed 100% success rate on BM and 91.2% on PB, with invalid rate of 0% and 9.8%, respectively.

Preanalytical variances tracked include delayed sample, misrouted sample, mislabelled sample, order issue, incomplete/incorrect or no requisition received, transport issue, clotted sample, wrong anticoagulant used, excess or low volume received, and other. Of these, sample delays, cell count concentration, and low total cells received are significantly associated with karyotype failure. Receiving 10 million total cells or less is associated with invalid studies (P < 0.0001) with 12% failure rate (10/84).  Cell count concentration of <4 million per ml is also associated with invalid studies (P<0.0001) with 9% failure rate (12/133). Delay from sample collection to test initiation is also associated with invalid studies (P=0.0286) with 7% failure rate (5/76). Of delayed samples, the median transport days from samples with successful results vs those with invalid results were 3 (range 3-15) and 5 (range 3-16) days, respectively.  When all three significant variances were present, karyotype failure rate was 40% (2/5), compared to karyotype failure rate of only 0.8% (5/627) when none of these three factors were present (P=0.001). A major reason for sample delay was customs clearance for Canadian samples.

Conclusions: The first 1000 myeloMATCH patient study demonstrated that rapid screening of diagnostic AML/MDS samples for karyotype analysis at an MDNet laboratory has been highly successful. The overall failure rate of 2.4% is much lower than the 6-10% published rates. Sample delays, low total cells, and low cell count concentration are significant contributing factors to karyotype failure. These results help inform accrual sites with opportunities to improve screening success by optimizing sample collection with sufficient cells and maximizing the chance for speedy customs clearance during sample transportation.

Funding: NIH/NCI grants U10CA180888, U10CA180819
Shane McClung: No relevant conflicts of interest to declare.